home > ebr > autumn 2013 > cellular therapy


Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.


News and Press Releases

Molecular Devices adds proprietary patient-derived organoid technology with acquisition of Cellesce

First-of-its-kind technology from Cellesce creates consistent patient-derived organoids for large scale drug screening. Acquisition strengthens Molecular Devicesí position as a 3D biology solutions innovator. Combined expertise will accelerate industry adoption of physiologically-relevant cell models for drug discovery.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement